1. Scrip
  2. >>Conferences
  3. >>ASCO

Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy

 
• By Alaric DeArment

The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.

L-R: Chirfi Guindo, chief marketing officer, human health; Marjorie Green, head of late-stage oncology development; Gregory Lubiniecki, VP late oncology development; Eliav Barr, chief medical officer, Merck Research Laboratories; Dean Li, president, Merck Research Laboratories • Source: Alaric DeArment

Fresh off a raft of data presentations at the American Society of Clinical Oncology’s 2023 meeting, Merck & Co., Inc. laid out an oncology product development strategy in which immuno-oncology and antibody-drug conjugates (ADC) will play a leading role, along with small-molecule drugs.

Executives from the company assembled for a 5 June investor event in Chicago to lay out how the company plans...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences

Novartis Heralds Watershed Ianalumab Data In Sjogren’s

 
• By Kevin Grogan

The Swiss major plans to submit the positive results from the NEPTUNUS program to health authorities globally in early 2026.

MFN And Confidential Pricing: What Experts Said

 
• By Anju Ghangurde

Experts at a recent summit discussed the complexities and impact of US MFN pricing from a payer perspective and emphasized the importance of a centralized purchaser of drugs to effectively negotiate prices. The potential rise of 'confidential discounts' in Germany was another key talking point.

How Korean Biotech Can Overcome Investment, Regulatory Hurdles

 
• By Jung Won Shin

At recent conferences in Seoul, participants discussed various hurdles for growth in the Korean biotech ecosystem and potential opportunities such as the ongoing collaborations between Korea and Japan.